GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Cooper Companies Inc (NAS:COO) » Definitions » Altman Z2-Score

The Cooper (The Cooper) Altman Z2-Score : 4.49 (As of Apr. 28, 2024)


View and export this data going back to 1983. Start your Free Trial

What is The Cooper Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

The Cooper has a Altman Z2-Score of 4.49, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for The Cooper's Altman Z2-Score or its related term are showing as below:

COO' s Altman Z2-Score Range Over the Past 10 Years
Min: 3.36   Med: 3.96   Max: 7.36
Current: 4.49

During the past 13 years, The Cooper's highest Altman Z2-Score was 7.36. The lowest was 3.36. And the median was 3.96.


The Cooper Altman Z2-Score Historical Data

The historical data trend for The Cooper's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Cooper Altman Z2-Score Chart

The Cooper Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.65 3.52 5.70 4.07 4.57

The Cooper Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.40 4.40 4.47 4.57 4.49

Competitive Comparison of The Cooper's Altman Z2-Score

For the Medical Instruments & Supplies subindustry, The Cooper's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Cooper's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where The Cooper's Altman Z2-Score falls into.



The Cooper Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

The Cooper's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.0689+3.26*0.5782+6.72*0.0432+1.05*1.7742
=4.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Jan. 2024:
Total Assets was $12,033 Mil.
Total Current Assets was $1,794 Mil.
Total Current Liabilities was $965 Mil.
Retained Earnings was $6,957 Mil.
Pre-Tax Income was 120 + 106.4 + 118.8 + 65.6 = $411 Mil.
Interest Expense was -29.9 + -26.3 + -26.8 + -26.1 = $-109 Mil.
Total Liabilities was $4,337 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(1793.9 - 964.9)/12032.6
=0.0689

X2=Retained Earnings/Total Assets
=6957.3/12032.6
=0.5782

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(410.8 - -109.1)/12032.6
=0.0432

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(7695.1 - 0)/4337.3
=1.7742

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

The Cooper has a Altman Z2-Score of 4.49 indicating it is in Safe Zones.


The Cooper  (NAS:COO) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


The Cooper Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of The Cooper's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


The Cooper (The Cooper) Business Description

Traded in Other Exchanges
Address
6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, USA, 94583
The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.
Executives
Gary S Petersmeyer director 3400 CENTRAL AVENUE, SANTA CLARA CA 95051
Robert S Weiss director, officer: EVP and CFO 6140 STANERIDGE MALL RES #590, PLEASSANTON CA 94503
Agostino Ricupati officer: Sr. VP, Finance & Tax C/O THE COOPER COMPANIES, INC., 6140 STONERIDGE MALL ROAD, SUITE 590, PLEASANTON CA 94588
Warner Gerard H Iii officer: President, CooperVision, Inc. C/O COOPER COMPANIES INC., 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON CA 94583
Jody S Lindell director 2536 FILLMORE ST., SAN FRANCISCO CA 94115
Cynthia L Lucchese director 7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260
Nicholas Khadder officer: VP, General Counsel & Corp Sec 2836 JOHNSON AVENUE, ALAMEDA CA 94501
Daniel G Mcbride officer: VP and Senior Counsel 5 EL CORTE, ORINDA CA 94563
Brian G Andrews officer: Treasurer 4300A 17TH STREET, SAN FRANCISCO CA 94114
Maria Rivas director C/O MEDIDATA SOLUTIONS, INC., 350 HUDSON STREET, 9TH FLOOR, NEW YORK NY 10014
White Albert G Iii officer: VP & Treasurer 6790, SPRINGDALE COURT, VICTOR NY 14564
Teresa S Madden director 414 NICOLLET MALL, MINNEAPOLIS MN 55401
Robert D Auerbach officer: President, CSI C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Holly R Sheffield officer: EVP, CSO C/O THE COOPER COMPANIES, INC., 6140 STONERIDGE MALL ROAD, SUITE 590, PLEASANTON CA 94588
Mark J Drury officer: VP, General Counsel & Sec. C/O COOPERCOMPANIES, 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON CA 94583